The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation.
Abstract
ABSTRACT: Somatostatin receptor-targeted α-therapy using α-emitter 225Ac-labeled somatostatin analogs has been suggested as a treatment option in advanced metastatic neuroendocrine tumors (NETs) failing treatment with β-emitters, such as 177Lu or 90Y. Thymus NETs are rare and usually more aggressive than other neuroendocrine tumor entities. We present here a case with β-radiation refractory metastatic thymus NET, who demonstrated an excellent therapy response (molecular and morphological remission, as well as significantly improved clinical symptoms) after 225Ac-DOTATOC-targeted α-therapy, without any adverse effects during the treatment or in the follow-up period.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“No adverse effects observed after 225Ac-DOTATOC TAT in patients with metastatic neuroendocrine tumors failing β-PRRT.”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [163]
Citations
Cites
Ballal, S., Yadav, M. P., Bal, C., Sahoo, R. K., & Tripathi, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04567-2 · Cited by 215
Gaur, P., Leary, C. C., & Yao, J. C. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181dd4ec4 · Cited by 180
Supply and clinical application of Actinium-225 and Bismuth-213.
Morgenstern, A., Apostolidis, C., & Bruchertseifer, F. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.02.003 · Cited by 141
Targeted Alpha Therapy: Current Clinical Applications
Liberal, F. D. C. G., O’Sullivan, J. M., McMahon, S. J., & Prise, K. M. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.3576 · Cited by 103
Navalkissoor, S., & Grossman, A. B. (2018) · Neuroendocrinology · doi:10.1159/000494760 · Cited by 99
Neuroendocrine neoplasms of the mediastinum.
Wick, M. R., & Rosaí, J. (1991) · PubMed · Cited by 82
Targeted alpha therapy with bismuth‐213 and actinium‐225: Meeting future demand
Bruchertseifer, F., Kellerbauer, A., Malmbeck, R., & Morgenstern, A. (2019) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3792 · Cited by 68
Neuroendocrine tumors of the thymus and mediastinum
Bohnenberger, H., Dinter, H., König, A. O., et al. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.02.02 · Cited by 52
Zhang, J., Kulkarni, H., & Baum, R. P. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002915 · Cited by 41
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68
Self-citation
Metadata
- Authors
- Zhang, J., Kulkarni, H. R., & Baum, R. P.
- Affiliations
- National University of Singapore (SG)
- Zentralklinik Bad Berka (DE)
- Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany.
- Corresponding author
- Zhang, Jingjing
- Venue
- Clinical Nuclear Medicine
- Published
- 2021-07-08
- Volume
- 46
- Issue
- 12
- Pages
- 1030-1031
- ISSN
- 0363-9762 (ISSN-L)
- 1536-0229
- OpenAlex
- W3180671804
- Cited by
- 19
- References
- 9
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 7 · 2022: 3
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- thymic neuroendocrine tumors, metastatic neuroendocrine tumors, radiolabeled somatostatin analogs, treatment response
- MeSH terms
- Actinium, Humans, Yttrium Radioisotopes, Octreotide, Receptors, Somatostatin, Neuroendocrine Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
